• Mashup Score: 2
    Cutting-Edge Trials in Structural Heart Disease at The Texas Heart Institute - 9 month(s) ago

    Mitral and tricuspid valvular disease have been managed surgically; however, multiple transcatheter technologies have diversified the therapeutic arsenal and expanded the number of patients eligible for treatment. These new technologies and active trials currently being performed at The Texas Heart Institute will be highlighted.Transcatheter edge-to-edge repair (TEER) with MitraClip (Abbott Structural Heart) plays an important role in the management of degenerative and functional mitral regurgitation (MR). Despite its success, the limitations of MitraClip include challenging anatomy that may not be amenable to TEER, the common need for multiple devices, risk of device-related mitral stenosis, and a not-trivial rate of residual MR.1 Delivered via a 22F sheath, the PASCAL device (Edwards Lifesciences) offers several improvements.2 Its 3-catheter system (including a guide, steerable, and implantation catheter) offers easy maneuverability in 3 independent planes. It has a spacer that fills

    Source: meridian.allenpress.com
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Texas_Heart
      Texas_Heart

      Cutting-edge trials in structural heart disease at The Texas Heart Institute | #THIPubs #GVSilva | @Texas_Heart #THIJournal https://t.co/EHxB1llQzQ

  • Mashup Score: 0
    Mendeley - 9 month(s) ago

    AmSECT’s Journal of ExtraCorporeal Technology is the premier global source of the most current research and information related to extracorporeal technology.

    Source: ject.edpsciences.org
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Texas_Heart
      Texas_Heart

      3D-Printed silicone anatomic patient simulator to enhance training on cardiopulmonary bypass | #THIPubs #YaxinWang #PASmith #PSPeak #DLAdams #TNCrane #Perfusion | @amsectperfusion #JECT https://t.co/9sXOzcX2mS

  • Mashup Score: 0
    The Past, Present, and Future of Complex Aortic Intervention - 9 month(s) ago

    Albert Einstein once said, “The distinction between the past, present and future is only a stubbornly persistent illusion.”So much of what is done with complex aortic surgical interventions is a direct outgrowth of what has been done, what is being done, and what is intended to be accomplished.The first successful aortic aneurysm repair was performed by Dr Charles Dubost in 1951; he replaced an infrarenal abdominal aorta aneurysm using a cadaver homograft harvested weeks earlier.1 This surgery culminated substantial efforts to repair damaged aortas using various techniques, including wiring the aorta with materials to induce thrombosis; proximal ligation of aortic aneurysms using metal tape, sutures, and autogenous tissue; and wrapping the aorta with cellophane and other materials. Dr Dubost’s success was made possible by pioneering vascular surgeons, including Dr Alexis Carrel (1873–1944),2 Dr Rudolph Matas (1860–1957),3 and Dr Oscar Creech (1916–1967),4 and contributed to further inn

    Source: meridian.allenpress.com
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Texas_Heart
      Texas_Heart

      The past, present, and future of complex aortic intervention | #THIPubs @Jcoselli_MD | @Texas_Heart #THIJournal https://t.co/LexPMny2RH

  • Mashup Score: 3
    Arterial Grafts in Coronary Artery Bypass Surgery: Who, When, and Why - 9 month(s) ago

    When selecting conduits for coronary artery bypass, long-term patency, survival benefit, and patient factors such as coronary atherosclerotic burden and comorbid conditions are the primary influences on surgical decision-making (Fig. 1). Previous studies have shown that multiple arterial conduits offer a survival benefit,1 but the observational design of this work makes the findings subject to patient selection bias. The Arterial Revascularization Trial was a prospective, randomized trial comparing bilateral internal thoracic arteries (ITAs) with single ITA conduits plus either a vein or radial artery (RA) conduit.2 The study did not demonstrate the survival benefit that observational studies have shown. With a crossover rate of 14% and 21.8% of patients in the single-ITA group receiving RA grafts, the findings are far from conclusive. In a post hoc, as-treated analysis, a survival benefit was seen with 2 arterial grafts—left ITA (LITA) plus right IT or RA—compared with a single arteri

    Source: meridian.allenpress.com
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Texas_Heart
      Texas_Heart

      Arterial grafts in coronary artery bypass surgery: Who, when, and why | #THIPubs @LaurenBarronMD | @Texas_Heart #THIJournal https://t.co/OVnANas3Md

  • Mashup Score: 0
    Leveraging Innovation to Mitigate Risk During Heart Surgery - 9 month(s) ago

    Innovation is not necessarily about the “next big thing” according to Mehta.1 Instead, innovation can occur by combining existing technologies, developing small ideas that compound, or evolving to address problems that have arisen from previous innovations that yielded unpredictable consequences. Innovation in the field of cardiovascular surgery is no different. As the field becomes progressively less invasive through innovation, patients who require open cardiac surgery are increasingly complex and carry increased risk. Patients with ischemic cardiomyopathy at high risk for morbidity often require surgical revascularization and valve interventions; however, risk factors such as diminished ejection fraction, redo operation, and multiple comorbidities compound perioperative morbidity and operative mortality. This report will define high-risk cardiac surgery and discuss how surgeons can leverage innovation to mitigate risk.The Surgical Treatment for Ischemic Heart Failure (STICH) trial r

    Source: meridian.allenpress.com
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Texas_Heart
      Texas_Heart

      Leveraging innovation to mitigate risk during heart surgery | #THIPubs @MarcMoonMD | @Texas_Heart #THIJournal https://t.co/WbLCfGneaX

  • Mashup Score: 3
    The James T. Willerson, MD, Editor's Choice Award - 9 month(s) ago

    In 2021, The Texas Heart Institute Board of Trustees created the James T. Willerson, MD, Editor’s Choice Award to honor his standards for excellence in research and scientific publishing. That year, 3 groups of authors whose articles were published in The Texas Heart Institute Journal received an award.Going forward, 2 primary authors will be recognized annually for their work on a Clinical Investigation, Laboratory Investigation, or Systematic Review that has been published in The Journal. Each author, one of whom will be an early-career professional, will receive a certificate and $5,000.Authors can now apply for the Editor’s Choice award when they submit their eligible original research papers to The Journal (Application Details). Winners of the 2023 awards will be recognized during a live ceremony from the Denton A. Cooley Auditorium in early 2024. The ceremony will be livestreamed to accommodate out of town recipients and their guests.Dr Willerson was an exemplary clinician who pl

    Source: meridian.allenpress.com
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Texas_Heart
      Texas_Heart

      The James T. Willerson, MD, Editor's Choice Award | #THIPubs #DrZKrajcer | @Texas_Heart #THIJournal https://t.co/ZOjjXafKro

Load More